Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History C… (NCT07424235) | Clinical Trial Compass
CompletedNot Applicable
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort
60 participantsStarted 2015-01
Plain-language summary
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration that leads to progressive and irreversible vision loss. The course of visual decline varies widely among patients, and it is not always clear which anatomical features of the retina are associated with faster loss of vision.
This retrospective observational study aims to describe the natural history of vision loss in patients with geographic atrophy who have characteristics similar to those enrolled in recent clinical trials. The study will analyze previously collected clinical and imaging data from patients followed during routine clinical care at a single center.
The main goal of the study is to evaluate the relationship between changes in visual function and retinal anatomical features, such as the size and location of atrophic lesions and retinal layer integrity, using fundus autofluorescence and optical coherence tomography images.
No treatments or study procedures are performed as part of this research. All data used in the study were collected during standard clinical practice and analyzed retrospectively.
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female patients aged 50 years or older at baseline.
* Diagnosis of geographic atrophy secondary to dry age-related macular degeneration in the study eye.
* Well-demarcated geographic atrophy lesions confirmed by fundus autofluorescence imaging, with a total lesion area between 2.5 mm² and 17.5 mm².
* Presence of hyperautofluorescence in the junctional zone of the geographic atrophy lesion.
* Best-corrected visual acuity between 45 and 83 ETDRS letters at baseline.
* Availability of longitudinal clinical and imaging data with at least 6 months of follow-up.
Exclusion Criteria:
* Evidence or history of neovascular (wet) age-related macular degeneration in the study eye.
* Prior intravitreal therapy or systemic treatments specifically targeting age-related macular degeneration.
* Geographic atrophy lesions contiguous with peripapillary atrophy.
* Coexisting ocular diseases that could independently affect visual acuity or retinal structure.
* Incomplete or poor-quality clinical or imaging data precluding reliable assessment of study outcomes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Loss of Best-Corrected Visual Acuity of ≥15 ETDRS Letters
Timeframe: From baseline to the last available follow-up visit, with a minimum follow-up of 6 months and a preferred follow-up of 12 to 15 months.